Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

NCT03937219 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

855

Enrollment

INDUSTRY

Sponsor class

Conditions

Renal Cell Carcinoma

Interventions

DRUG: Cabozantinib
BIOLOGICAL: Nivolumab
BIOLOGICAL: Ipilimumab
DRUG: Cabozantinib-matched placebo

Sponsor

Exelixis